Skip to main content

Oncology Programs

Our oncology programs include:

  • A comprehensive array of advanced, state-of-the-art cancer treatment services and diagnostic technology—including one of the regions' most advanced 64-slice CT scanners
  • Multi-specialty team approach to coordinate the best cancer treatment options available
  • Surgical options and procedures provided by highly skilled, board-certified surgeons
  • Access to cancer-related information, education, and support
  • Chemotherapy administration by nationally certified oncology nurses
  • Affiliates of UK Markey Cancer Center to provide radiation therapy close to home
  • Cancer registry that collects data on cancer type, stage, and treatment results, and offers lifelong patient follow-up
  • Ongoing monitoring and improvement of care
  • Information about clinical trials and new treatment options
  • Support groups for patients, families, and caregivers

Program Outcomes

Kentucky has one of the highest rates of cancer in the nation, with the disease being one of the leading causes of death in the state. St. Claire HealthCare (SCH) continues to do its part in educating the public and lowering the cancer death rate in Northeastern Kentucky. In 2016, SCH joined an effort with the UK Markey Cancer Center to "Terminate Lung Cancer." The goal of Terminate Lung Cancer (TLC) is to increase education and access to screening and preventive measures, including tobacco cessation resources.

SCH's cancer prevention and education efforts, along with results from 2018:

Tobacco Cessation

Over the course of the year, 17 participants enrolled in St. Claire HealthCare’s Freedom From Smoking class through the American Lung Association, with eight quitting tobacco use by the end of the program. In an effort to make the class more accessible SCH now offers the class via zoom so that participants can access the class via any smart device.

In conjunction with Rowan County Senior High School, the American Lung Association Not-On-Tobacco (NOT) tobacco cessation program is now offered to students at RCSHS. Five facilitators including SCH and RCSHS staff collaborated to offer the program in 2018 with eight students volunteering to participate, four actively participating and one adolescent completing the program now living tobacco-free.

St. Claire Oncology proudly staffs three Certified Tobacco Treatment Specialists that have completed the 27-hour online UK BREATHE Tobacco Treatment Specialist Training.  

Lung Cancer Symposium

Through the Terminate Lung Cancer program St. Claire hosted 94 attendees at the 3rd Annual Lung Cancer Symposium in September to further educate the public and medical community in our region about the effects of lung cancer and how to prevent it. This year the symposium featured speakers from the NE KY community, state and national level featuring a keynote speaker from the Center for Disease Control and Prevention.

SWOG Membership

St. Claire HealthCare is an Affiliate Member of SWOG and participates in cancer research studies, including trials conducted within the NCI’s National Clinical Trials Network. SWOG is a cancer research cooperative group which designs and conducts multidisciplinary clinical trials to improve the practice of medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors. This membership allows St. Claire to bring National Clinical Trials to our patients close to home in a familiar and comfortable setting.

National Colorectal Cancer Prevention Clinical Trial

St. Claire HealthCare is collaborating on a nationwide research study to test whether two drugs can help prevent second cancers and the formation of new precancerous polyps, known as adenomas, in patients who have already battled colorectal cancer. The Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) clinical trial is managed by the international cancer trials group SWOG, with public support from the National Cancer Institute (NCI). PACES is testing these two drugs in colorectal cancer survivors after previous research showed that they held promise for people currently undergoing treatment. That previous study showed the drugs significantly reduced the chances of people developed high-risk cancers.

Click to Learn More